{"id":55735,"date":"2026-01-28T22:12:51","date_gmt":"2026-01-28T14:12:51","guid":{"rendered":"https:\/\/flcube.com\/?p=55735"},"modified":"2026-01-28T22:12:52","modified_gmt":"2026-01-28T14:12:52","slug":"sino-biopharms-tqa3605-meets-endpoint-in-hepatitis-b-phase-ii-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55735","title":{"rendered":"Sino Biopharm’s TQA3605 Meets Endpoint in Hepatitis B Phase II Trial"},"content":{"rendered":"\n

Sino Biopharmaceutical Ltd<\/strong> (HKG: 1177<\/a>) announced that its Category\u202f1 drug TQA3605<\/strong> has met the primary endpoint in a Phase\u202fII study<\/strong> for patients with chronic hepatitis\u202fB virus (HBV) infection. The HBV core protein allosteric modulator (CpAM) demonstrated ~90% viral suppression<\/strong> when combined with nucleos(t)ide analogues (NAs), with no similar product approved globally.<\/p>\n\n\n\n

Clinical Trial Results & Regulatory Status<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Sino Biopharmaceutical Ltd (HKEX.01177)<\/td><\/tr>
Drug<\/strong><\/td>TQA3605 (HBV core protein allosteric modulator)<\/td><\/tr>
Indication<\/strong><\/td>Chronic hepatitis\u202fB virus (HBV) infection<\/td><\/tr>
Trial<\/strong><\/td>Phase\u202fII, Category\u202f1 drug<\/td><\/tr>
Mechanism<\/strong><\/td>Inhibits multiple HBV genotypes, no cross\u2011resistance with NAs<\/td><\/tr>
Primary Endpoint<\/strong><\/td>HBV DNA <20\u202fIU\/mL at 24 weeks<\/td><\/tr>
Efficacy<\/strong><\/td>~90% response rate (all dose groups) vs. control (p\u202f<\u202f0.0001)<\/td><\/tr>
Safety<\/strong><\/td>Favorable profile, adverse reaction rate comparable to control<\/td><\/tr>
Strategic Significance<\/strong><\/td>No approved CpAM worldwide; first\u2011in\u2011class potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Competitive Advantage<\/h2>\n\n\n\n